Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-Positive Early Stage Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Lapatinib|DRUG: Pegfilgrastim
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: GlaxoSmithKline